GSK126   Click here for help

GtoPdb Ligand ID: 7012

Synonyms: GSK 126 | GSK-126 | GSK2816126
PDB Ligand
Compound class: Synthetic organic
Comment: GSK126 is a potent and selective small-molecule inhibitor of EZH2 (KMT6) methyltransferase activity [2]. This is likely to be the ligand with the extended reseaerch code GSK2816126, which has anti-lymphoma potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 95.05
Molecular weight 526.31
XLogP 6.14
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCC(n1cc(c2c1cc(cc2C(=O)NCc1c(C)cc([nH]c1=O)C)c1ccc(nc1)N1CCNCC1)C)C
Isomeric SMILES CC[C@@H](n1cc(c2c1cc(cc2C(=O)NCc1c(C)cc([nH]c1=O)C)c1ccc(nc1)N1CCNCC1)C)C
InChI InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)/t22-/m0/s1
No information available.
Summary of Clinical Use Click here for help
GSK2816126 is being evaluated in Phase 1 clinical trial NCT02082977, in patients with various types of lymphoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02082977 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma Phase 1 Interventional GlaxoSmithKline